JAKKS Pacific, Inc., today announced a worldwide licensing agreement with MORF LLC for its MorfBoard™ line of products for kids and adults.

About the EMERALD-2 Study EMERALD-2 (MORF-057-202) is a global phase 2b randomized, double-blind, placebo-controlled trial of MORF-057 in patients with moderate-to-severe ulcerative colitis.

MORF-057 well tolerated in all dose cohorts MORF-057 achieved greater than 95% mean receptor occupancy of α4β7 integrin at three highest dose levels; demonstrates ability to saturate α4β7 ...

One of the leading designers, marketers and distributors of children’s toys and consumer products, JAKKS Pacific, Inc. (NASDAQ: JAKK), today announced a worldwide licensing agreement with MORF LLC for ...

Detailed price information for Morphic Holding Inc (MORF-Q) from The Globe and Mail including charting and trades.